ストックスクリーナーアプリを入手
107.62
1.90%
-2.08
前日終値:
$109.70
開ける：
$108.91
24時間の取引高:
68,254
Relative Volume:
0.64
時価総額：
$2.11B
収益：
$152.42M
当期純損益:
$45.24M
株価収益率:
42.88
EPS:
2.51
ネットキャッシュフロー:
$6.97M
1週間 パフォーマンス:
-0.49%
1か月 パフォーマンス:
-6.96%
6か月 パフォーマンス:
+10.53%
1年 パフォーマンス:
+47.22%
1日の値動き範囲:
$106.43
$109.82
1週間の範囲:
$106.43
$112.61
52週間の値動き範囲:
$67.72
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
名前
Ligand Pharmaceuticals Inc
セクター
電話
858-550-7500
住所
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
107.62 | 2.11B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-03 | 開始されました | Oppenheimer | Outperform |
| 2024-07-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 再開されました | Stephens | Overweight |
| 2021-02-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-06 | 開始されました | Barclays | Overweight |
| 2020-03-24 | ダウングレード | Argus | Buy → Hold |
| 2020-03-10 | 開始されました | Guggenheim | Neutral |
| 2020-02-06 | 開始されました | The Benchmark Company | Buy |
| 2019-09-19 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-10-29 | アップグレード | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-11 | 繰り返されました | Argus | Buy |
| 2018-08-17 | 開始されました | Goldman | Neutral |
| 2018-08-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 開始されました | Argus | Buy |
| 2017-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-09-05 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-05 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 開始されました | Sidoti | Buy |
| 2016-03-03 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Swiss National Bank Has $3.86 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand’s Second Quarter Financial Results to be Reported August 3rd - Business Wire
Victory Capital Management Inc. Buys 200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.com - Defense World
US Bancorp DE Acquires 98 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Atria Investments Inc - Defense World
Bank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Smartleaf Asset Management LLC Buys 221 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Phar - GuruFocus.com
Mutual of America Capital Management LLC Has $307,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
CFO’s Major Stock Sale Shakes Up Ligand Pharma - TipRanks
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock - Investing.com
Truist Financial Corp Lowers Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
LGND: First Steps into Cell & Gene Therapy - Research Tree
Ligand CEO and CFO Heading to Miami: Key Investor Access Points for LGND Shareholders - StockTitan
Ligand to Participate in March Investor Conferences - Yahoo Finance
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
Principal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth - TipRanks
Ligand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3%Should You Buy? - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Releases Quarterly Earnings Results - MarketBeat
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Ligand Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
New York State Common Retirement Fund Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Ligand: Q4 Earnings Snapshot - mySA
Ligand Pharmaceuticals' Q4 Core Adjusted Net Income, Total Revenue Rise; 2025 Guidance Set - Marketscreener.com
Ligand Pharmaceuticals Incorporated Reaffirms the Earnings Guidance for the Year 2025 - Marketscreener.com
Ligand Pharma Slips To Loss In Q4; Confirms FY25 OutlookUpdate - Nasdaq
LIGAND PHARMACEUTICAL Earnings Results: $LGND Reports Quarterly Earnings - Nasdaq
Ligand Pharmaceuticals Q4 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Ligand: Q4 Earnings Snapshot -February 27, 2025 at 07:24 am EST - Marketscreener.com
Earnings Flash (LGND) Ligand Pharmaceuticals, Posts Q4 Revenue $42.8M, vs. FactSet Est of $39.0M - Marketscreener.com
Ligand Pharmaceuticals Inc Q4 Earnings Summary - Nasdaq
Ligand Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stake Reduced by Rhumbline Advisers - Defense World
Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need T - GuruFocus.com
Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Ligand Pharma Enters $75M Agreement with Castle Creek - TipRanks
Ligand Invests $75 Mln Royalty Financing In Castle Creek Biosciences - Nasdaq
Ligand backs Castle Creek's gene therapy with $75 million investment By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals Inc (LGND) 財務データ
収益
当期純利益
現金流量
EPS
Ligand Pharmaceuticals Inc (LGND) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Espinoza Octavio | Chief Financial Officer |
Mar 04 '25 |
Sale |
115.03 |
5,000 |
575,148 |
18,879 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):